Roller Bottle Culturer Apparatus Adherent Culture Cell Cultures Bottle Roller Incubator

Name: Roller Bottle Culturer Apparatus Adherent Culture Cell Cultures Bottle Roller Incubator
Brand: CHINNOFI PHARMACEUTICAL MACHINERY CO., LTD.
SKU: 1951229545

Jiangsu, ChinaCHINNOFI PHARMACEUTICAL MACHINERY CO., LTD.

US$5,000.00-22,000.00

1 Piece

Product profile

Customization

Available

Application

Laboratories, Pharmaceutical Factory, Veterinary

Disposable

Model NO.

CGIII series

Injection Site

Intramuscular

Material

Stainless Steel

Usage

Medical

Warranty

1 Year

Partner

Incubator

Culture Application

Cell Culture

Rolling Method

Automatic and Speed Setable

Cell Culture Method

Adherent Culture and Suspension Culture

Precision

High Precision

Certification

CE, GMP

Voltage

220V

Computerized

Customized

Condition

New

Type

Roller Bottle

Finished Dosage Form

Bottle Roller

After-Sales Service

10 Year

Transport Package

Wooden Case

Specification

3000~15000ml

Trademark

CHINNOFI

Origin

China

Production Capacity

5000 Pieces/Year

Company profile

Importers and ExportersHigh Repeat Buyers ChoiceExperienced TeamExhibition Experience

CHINNOFI PHARMACEUTICAL MACHINERY CO., LTD.

Jiangsu, China

Business Type: Manufacturer/FactoryExport Year: 2016-10-18Average Response Time: ≤5.02hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CIF

AI-Powered supplier vetting

SummaryThe supplier is a limited trading company with 11 employees, offering pharmaceutical, food-processing, and chemical equipment, including reactors, filling machines, autoclaves, water systems, dryers, and packaging lines. It reports ISO 9001 and GMP certification, available SDK support, R&D and customization capabilities, new product launches during the past year, and extensive export coverage. R&D engineer experience is reported at 41–50 years in aggregate, with 21–30 quality-control staff and an off-peak lead time of 2–3 months. Service infrastructure includes overseas agents or branches, an overseas showroom, and participation in the CPHI trade show. Financial records are indicated for 2020–2022, but no financial performance values are provided. Supplier service procedures exist, although the assessment procedure has no records. Raw-material traceability and several sustainability controls remain unknown. No specific customer cases are provided.

CertificationsThe supplier reports holding ISO 9001 and GMP certifications. These are explicit quality and manufacturing-system credentials relevant to its equipment scope.

After-Sales capabilityThe supplier reports 15 qualified service-capability suppliers, a corrective and preventive action procedure with follow-up records, overseas agents or branches, an overseas showroom, and service coverage in Europe and America. However, the service-capability assessment procedure has written procedures but no records, limiting verification depth.

R&D capabilityThe supplier reports an available SDK, new products launched during the past year, customization from samples and designs, and total R&D engineer experience of 41–50 years. These points explicitly support established innovation and development capability.

Production capacityThe supplier states that it manufactures general equipment and pharmaceutical, food-processing, and chemical equipment, with a broad product range, 21–30 quality-control staff, and a reported off-peak lead time of 2–3 months. An audit was conducted by BV, but the audit result is recorded as 0 without an explanatory interpretation, so production-system performance cannot be fully assessed.

Customization capabilityThe supplier explicitly offers customization from samples and customization from designs. This directly demonstrates both sample-based and design-based customization services.